SCHEMBL1303746

SCHEMBL1303746

NC(=O)CNCc1ccccn1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.59
CHRM2 P08172 1/20 0.53
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 3/20 0.50
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
POLB P06746 3/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
HTT P42858 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
GAA P10253 1/20 0.49
HPGD P15428 3/20 0.48
RECQL P46063 1/20 0.48
ALOX15 P16050 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
LMNA P02545 1/20 0.48
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3319189 0.92 CHRM2 (0.57) SMN1; SMN2CHRM2ALDH1A1KDM4ENPC1
SCHEMBL29832698 0.86 SMN1; SMN2 (0.62) SMN1; SMN2CHRM2ALDH1A1KDM4ENPC1
SCHEMBL472123 0.84 SMN1; SMN2 (0.61) SMN1; SMN2CHRM2ALDH1A1KDM4ENPC1
SCHEMBL6302679 0.83 CHRM2 (0.58) SMN1; SMN2CHRM2ALDH1A1KDM4ENPC1
SCHEMBL12831873 0.83 SMN1; SMN2 (0.59) SMN1; SMN2CHRM2ALDH1A1KDM4ENPC1
SCHEMBL3395752 0.83 SMN1; SMN2 (0.59) SMN1; SMN2CHRM2ALDH1A1KDM4ENPC1
SCHEMBL18160698 0.83 CHRM2 (0.53) SMN1; SMN2CHRM2ALDH1A1KDM4ERAB9A
SCHEMBL13793636 0.80 SMN1; SMN2 (0.56) SMN1; SMN2CHRM2ALDH1A1KDM4ENPC1
SCHEMBL14067286 0.80 CHRM2 (0.61) SMN1; SMN2CHRM2ALDH1A1KDM4ENPC1
SCHEMBL230222 0.79 CHRM2 (0.70) SMN1; SMN2CHRM2ALDH1A1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2462141-B1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2017-09-27 EP claimed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 US claimed
US-20120277228-A1 Novel Azaheterocyclic Compounds MERCK PATENT GMBH (DE) 2012-11-01 US claimed
EP-2462141-A1 NOVEL AZAHETEROCYCLIC COMPOUNDS Merck Patent GmbH (DE) 2012-06-13 EP claimed
US-RE50878-E1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2026-05-05 US disclosed
WO-2023011573-A1 AROMATIC ACETYLENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF 浙江海正药业股份有限公司 2023-02-09 WO disclosed
EP-3932935-A1 ANTIBACTERIAL PEPTIDES Centre National de la Recherche Scientifique (FR) 2022-01-05 EP disclosed
US-10772891-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SUISSE SA (CH) 2020-09-15 US disclosed
US-20180235976-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2018-08-23 US disclosed
US-9974791-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SUISSE SA (CH) 2018-05-22 US disclosed
US-20180094086-A1 NEAR INFRARED ABSORBING COMPOSITION, NEAR INFRARED CUT FILTER, METHOD OF MANUFACTURING NEAR INFRARED CUT FILTER, DEVICE, METHOD OF MANUFACTURING COPPER-CONTAINING POLYMER, AND COPPER-CONTAINING POLYMER FUJIFILM CORPORATION (JP) 2018-04-05 US disclosed
EP-2860179-B1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SUISSE SA (CH) 2018-03-14 EP disclosed
US-20120277228-A1 Novel Azaheterocyclic Compounds MERCK PATENT GMBH (DE) 2012-11-01 US disclosed
US-20110269757-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2011-11-03 US disclosed
EP-2344492-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GenKyoTex SA (CH) 2011-07-20 EP disclosed
US-7947712-B2 Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent WYETH LLC (US) 2011-05-24 US disclosed
WO-2010035221-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2010-04-01 WO disclosed
EP-2166010-A1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYO TEX SA (CH) 2010-03-24 EP disclosed
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof WYETH (US) 2008-10-30 US disclosed
US-5672615-A MATRIX-DEGRADING METALLOPROTEINASE INHIBITORS NOVARTIS CORPORATION (US) 1997-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269757-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX4, CYBB SMN1; SMN2 2521/4885CHRM2 1188/4885ALDH1A1 230/4885
US-20120277228-A1 Novel Azaheterocyclic Compounds PCNA, MCL1, MYC SMN1; SMN2 3720/4885CHRM2 4710/4885ALDH1A1 1038/4885
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof MMP8, MMP26, MMP9 SMN1; SMN2 598/4885CHRM2 2314/4885ALDH1A1 406/4885
US-20180235976-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX4, CYBB SMN1; SMN2 2521/4885CHRM2 1188/4885ALDH1A1 230/4885
US-10772891-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors NOX1, NOX4, CYBB SMN1; SMN2 2521/4885CHRM2 1188/4885ALDH1A1 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.